Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) - Treatment Options and Outcomes at a Large AML Referral Center

Julian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, Lina Kolloch, Philipp Berning, Simon Call, Matthias Floeth, Julia Marx, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2024) 144 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2024-203502

Published: 2024

Journal Articles

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 776.

https://doi.org/10.1182/blood-2024-204763

Published: 2024

Journal Articles

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Andrew F. Berdel, Julian Ronnacker, Daniela V. Wenge, Lina Kolloch, Philipp Berning, Linus Angenendt, Tobias Brix, Annette Westermann, Klaus Wethmar, Torsten Kessler, Andrea Kerkhoff, Rolf M. Mesters, Christian Reicherts, Jan-Henrik Mikesch, Wolfgang E. Berdel, Georg Lenz, Christoph Schliemann, Matthias Stelljes

Blood (2024) 144 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2024-193666

Published: 2024

Journal Articles

Comparable Survival for Fludarabine and Treosulfan Vs. Fludarabine and TBI As Conditioning Regimens in Patients with AML and MDS Undergoing Allogeneic Stem Cell Transplantation

Lina Kolloch, Philipp Berning, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Julian Ronnacker, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2023) 142 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2023-180078

Published: 2023

Journal Articles

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4911.

https://doi.org/10.1182/blood-2023-180723

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Matthias Stelljes, Katja Sockel, Matthias Floeth, Johannes Schetelig, Martin Bornhäuser, Christian Reicherts, Georg Lenz, Thomas Schröder, Rudolf Trenschel, Miroslaw Markiewicz, Hélène Labussière-Wallet, Péter Reményi, Fabio Ciceri, Friedrich Stölzel

Blood (2023) 142 (Supplement 1): 3526.

https://doi.org/10.1182/blood-2023-180816

Published: 2023

Journal Articles

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Blood (2022) 140 (Supplement 1): 9–11.

https://doi.org/10.1182/blood-2022-159962

Published: 2022

Journal Articles

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease

Matthias Floeth, Elena Beckmann, Christian Reicherts, Julia Marx, Simon Call, Inna Shaforostova, Eva Eßeling, Jorn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2022) 140 (Supplement 1): 7587–7588.

https://doi.org/10.1182/blood-2022-165424

Published: 2022

Journal Articles

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Daniela V. Wenge, Klaus Wethmar, Corinna Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt, Georg Evers, Simon Call, Andrea Kerkhoff, Cyrus Khandanpour, Torsten Kessler, Rolf M. Mesters, Christoph Schliemann, Jan-Henrik Mikesch, Christian Reicherts, Monika Brüggemann, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes

Blood (2021) 138 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2021-146459

Published: 2021

Journal Articles

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for the Assessment of Acute Intestinal GvHD and Prediction of Response to Immunosuppressive Therapy

Georg Evers, MD, Wolfgang Roll, Jörn Albring, Christian Reicherts, Benjamin Noto, Matthias Weckesser, Georg Lenz, Michael Schäfers, Matthias Stelljes, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-141536

Published: 2020

Journal Articles

Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial

Jürgen Finke, MD, Claudia Schmoor, Matthias Stelljes, MD, Andreas Burchert, MD, Peter Dreger, Eva-Maria Wagner, MD, Martin Bornhäuser, Kristina Sohlbach, MD, Natalie Schub, MD, Christian Reicherts, Guido Kobbe, Bertram Glass, Hartmut Bertz, MD, Olga Grishina

Blood (2018) 132 (Supplement 1): 210.

https://doi.org/10.1182/blood-2018-99-118999

Published: 2018

Journal Articles

High-Dose Melphalan-Based Sequential Conditioning Chemotherapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Christoph Groth, MD, Nina Kristin Steckel, MD, Jan-Henrik Mikesch, Rudolf Trenschel, MD, Hellmut Dietmar Ottinger, MD PhD, Carsten Müller-Tidow, Christoph Schliemann, Christian Reicherts, Eva Schmidt, Wolfgang E. Berdel, Georg Lenz, Markus Ditschkowski, Dietrich W Beelen, MD PhD, Matthias Stelljes, MD

Blood (2017) 130 (Supplement 1): 3205.

https://doi.org/10.1182/blood.V130.Suppl_1.3205.3205

Published: 2017

Journal Articles

A Phase I/II Study on the Anti-CD3/CD7 Immunotoxin Combination (T-GuardTM) for the Treatment of Steroid-Refractory Acute Gvhd

Christoph Groth, MD, Lenneke F J Groningen, Manita E J Bremmers, Frank W M B Preijers, Harry Dolstra, Tiago R Matos, Christian Reicherts, Eric G van Hooren, Ypke V J M van Oosterhout, John E Levine, MD, James L Ferrara, Nicole M A Blijlevens, Matthias Stelljes, MD, Walter J F M van der Velden

Blood (2017) 130 (Supplement 1): 513.

https://doi.org/10.1182/blood.V130.Suppl_1.513.513

Published: 2017

NARROW

Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) - Treatment Options and Outcomes at a Large AML Referral Center

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Comparable Survival for Fludarabine and Treosulfan Vs. Fludarabine and TBI As Conditioning Regimens in Patients with AML and MDS Undergoing Allogeneic Stem Cell Transplantation

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for the Assessment of Acute Intestinal GvHD and Prediction of Response to Immunosuppressive Therapy

Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial

High-Dose Melphalan-Based Sequential Conditioning Chemotherapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase I/II Study on the Anti-CD3/CD7 Immunotoxin Combination (T-GuardTM) for the Treatment of Steroid-Refractory Acute Gvhd

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only